WO2012010092A1 - 一种肽类物质的晶体及其制备方法和用途 - Google Patents
一种肽类物质的晶体及其制备方法和用途 Download PDFInfo
- Publication number
- WO2012010092A1 WO2012010092A1 PCT/CN2011/077382 CN2011077382W WO2012010092A1 WO 2012010092 A1 WO2012010092 A1 WO 2012010092A1 CN 2011077382 W CN2011077382 W CN 2011077382W WO 2012010092 A1 WO2012010092 A1 WO 2012010092A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- crystal
- compound
- formula
- organic solvent
- preparation
- Prior art date
Links
- 0 CCC**C(C=C)NC(*(*=C)N)=* Chemical compound CCC**C(C=C)NC(*(*=C)N)=* 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- This invention relates to crystals of compounds, and more particularly to crystals of a peptide material, methods of making the same, and uses. Background technique
- cyclic peptides having antifungal activity have been found in fermentation broths of certain fungi.
- These peptides mainly cyclic hexapeptides, are commonly referred to as echinocandins such as pneumocanin, WF11899, and echinocetin.
- Chemical modification of these cyclic peptides results in semi-synthetic antibiotics that can be used in clinical treatment.
- the compound represented by the formula I is a natural product obtained by fermentation and has a cyclic hexapeptide structure and is generally used as a raw material for synthesizing a compound represented by the formula ⁇ .
- the preparation method of the compound of the formula I can be referred to the preparation methods disclosed in U.S. Patents 5,202,309, 5,194,377 and 6,610,822.
- the acetate of the compound shown in formula ( (Caspofungin acetate, trade name Coss, CANCIDAS) is currently used as an antifungal drug for intravenous administration.
- the present invention aims to provide a novel crystal of the compound of formula I.
- Another object of the present invention is to provide a process for the preparation of the novel crystal.
- a crystal B of a peptide material having a structure as shown in Formula I wherein the crystal B has an X-ray powder diffraction (XRPD) pattern having peaks at the following 2 ⁇ angles: 3.2 ⁇ 0.2° , 5.4 ⁇ 0.2° , 6.2 ⁇ 0.2° , 9.3 ⁇ 0.2° ;
- XRPD X-ray powder diffraction
- the crystal B has a maximum peak at 155-165 °C on a differential scanning calorimetry (DSC).
- the crystal B has an infrared spectrum as shown in Fig. 3.
- a method for preparing a peptide material crystal B according to the invention as described above comprising the steps of:
- Peptide B crystals are obtained by cooling and/or adding another low polar solvent ( ⁇ ).
- the temperature in the step (a) is 10 to 80 ° C ; in the step (a), the total volume of the solution a, which contains the compound of the formula I, 20 to 250 rag / ml ; The total volume of the aqueous solution of the solvent (i) containing 0.1 to 15 v/v% of water ; the organic solvent (i) being selected from one or more of C, -4 alcohol and C 1 -4 ketone
- the organic solvent (ii) is selected from the group consisting of: a mixture of one or more of C 3 - 7 ester, hexanthene, n-heptanium, n-pentane, and dichloromethane.
- the organic solvent (i) is selected from the group consisting of one or more of methanol, ethanol, isobutanol, and acetone; the organic solvent ( ⁇ ) is selected from the group consisting of ethyl acetate and ethyl propyl acetate. a mixture of one or more of hexane, n-heptane, n-pentamidine, and methylene chloride.
- the volume ratio of the organic solvent (i) to the organic solvent (?) is 0.1 to 10:
- the temperature is lowered to lower the temperature of the solution obtained in the step (a) to 30 to - 50 V, in a third aspect of the invention, there is provided a use of the peptide material of the present invention as described above for the preparation of a compound of formula II;
- a use of the peptide material crystals provided by the present invention as described above is for the preparation of a medicament for treating fungal infections.
- a pharmaceutical composition comprising the peptide material crystal of the invention as described above and a pharmaceutically acceptable carrier.
- a process for the preparation of a pharmaceutical composition of the invention comprising the steps of:
- the peptide substance crystal provided by the present invention as described above and a pharmaceutically acceptable carrier are mixed to obtain a pharmaceutical composition of the present invention. Accordingly, the present invention provides a process for preparing crystals of the formula I which is simple in operation, fast and has a high crystal yield, and correspondingly obtained crystals.
- Figure 1 shows an X-ray powder diffraction pattern of crystal B of the compound of formula I.
- FIG. 2 shows a differential scanning calorimetry (DSC) pattern of crystal B of the compound of formula I.
- FIG. 3 shows the infrared (IR) spectrum of crystal B of the compound of formula I.
- Figure 4 shows an HPLC chromatogram of crystal B of the compound of formula I.
- Figure 5 shows an X-ray powder diffraction pattern of crystal A of the compound of formula I.
- Figure 6 shows an HPLC chromatogram of an amorphous powder of the compound of formula I.
- Figure 7 is a photomicrograph of crystal B of the compound of formula I.
- Figure 8 is a photomicrograph of crystal A of the compound of formula I. One 4 one
- the inventors have conducted extensive and intensive research and found that the use of certain solvents can dissolve the compound of formula I at a relatively low temperature, thereby obtaining crystals having a small amount of impurities, and the yield of crystals is also high.
- the present invention dissolves the compound of the formula I in an aqueous solution of an organic solvent (i), such as an aqueous solution of methanol, ethanol, propanol or the like, and then cools the solution or adds an organic solvent (ii) while cooling (e.g., ethyl acetate, acetic acid). Ethyl propyl ester, etc.) helps the precipitation of crystals, and finally crystal B is obtained.
- an organic solvent i
- an organic solvent i
- Ethyl propyl ester, etc. helps the precipitation of crystals, and finally crystal B is obtained.
- U.S. Patent No. 5,336,756 teaches that methanol, ethanol and other sterols are not suitable for crystallization. The inventors have found through experiments that crystals having a small impurity content and a good crystal form can be obtained by using these solvents, and the yield is also high.
- crystal means a solid in a specific arrangement of molecules or atomic complexes.
- the present inventors have found in the study that the compound of the formula I can be precipitated from the solution by dissolving the compound of the formula I in a suitable solvent and then using another solvent and/or a method of lowering the temperature.
- step (a) wherein the compound of formula I described in step (a) is dissolved at a temperature of from 10 to 80 V, preferably from 30 to 60 °C.
- the total volume of the solution a in the step (a) contains 20 to 250 mg/ml, preferably 50 to 200 mg/ml, of the compound of the formula I.
- the solvent (i) described in the step (a) is a mixture of one or more of d alcohol and - 4 ketone, preferably from one or more of methanol, ethanol, isobutanol and acetone. mixture.
- step (b) Wherein the temperature of the cooling described in the step (b) is from 30 to -50 ° C, preferably from 30 to - 10 ° C, more preferably from 25 to 10. C.
- the crystal B of the compound of formula I is obtained after step (a) according to the following procedure:
- the solvent (ii) described in the step (b') is a mixture of one or more of C 3 - 7 ester, hexanyl, n-heptane, n-pentane, dichloromethane, preferably from acetic acid a mixture of one or more of ethyl ester, ethyl propyl acetate, hexane, n-heptane, n-pentane, dichloromethane.
- the temperature described in the step (b') is from 30 to -50 V, preferably from 30 to -10 V, more preferably from 25 to 10 °C.
- volume ratio of the organic solvent (i) to the organic solvent (ii) in the step (b') is from 1 to 8, preferably from 2 to 5, more preferably from 3 to 4.
- the crystal B of the compound of the formula I prepared by the process of the present invention has a high purity, and thus it is more preferable to prepare the compound of the formula II. Identification and properties of crystal B of formula I
- the present inventors further studied the properties of the compound of the formula I after various uses thereof and instruments.
- X-ray powder diffraction also known as “X-ray polycrystalline diffraction (XRPD)
- XRPD X-ray polycrystalline diffraction
- An X-ray powder diffractometer is used to generate a series of diffraction patterns when X-rays are transmitted through the crystal. The different diffraction lines in the spectrum and their strengths are determined by a certain atomic group structure, thereby determining the crystal structure.
- the X-ray powder diffractometer of the D8 Advanced model acquires the spectrum with a copper radiation target at a scan speed of 2° per minute.
- the crystal B of the compound of the formula I of the present invention has a specific crystal morphology which has a specific characteristic peak in the X-ray diffraction pattern.
- the X-ray diffraction pattern of the crystal of the compound of the present invention has peaks at the following 2 ⁇ angles: 3.20 ⁇ 0.2 °, 5.42 ⁇ 0.2 °, 6.28 ⁇ 0.2 °, 9.28 ⁇ 0.2
- the X-ray diffraction pattern of the crystal of the compound of formula I of the present invention has substantially the same as that of Figure 1.
- DSC Differential calorimetric scanning analysis
- This method is commonly used in the art to detect various parameters such as phase transition temperature, glass transition temperature, and heat of reaction of a substance.
- the crystal of the compound of the formula I of the present invention has an exact melting point, i.e., it changes from a solid phase to a liquid phase in a narrow temperature range during heating.
- a DSC scan of the crystal can be obtained by using a DSC Q20 Differential Scanning Calorimeter at a temperature rise rate of 10 °C per minute from 25 °C to 200 °C.
- the crystal B of the compound of the formula I obtained by the process of the invention has a maximum peak in the vicinity of 155-165 ⁇ as determined by DSC, preferably the crystal B of the compound of the formula I according to the invention has the basic A consistent DSC spectrum, more preferably with a maximum peak at 163.63 ⁇ . .
- Infrared profiling can also be used to determine the crystal structure, and methods for its determination are known in the art.
- PE Specrum One B can be used, in KBr: sample two 200: 1 tablet, and in 400 - shed 0cm- 1
- the crystal B of the compound of the formula I of the present invention has a characteristic peak at the following wave number: 3346. 19 cm" 1 , 2926. 32 era” 1 , 2854. 48 cm” 1 , 2031. 95 cm” 1 , 1630. 12 cm- ', 1517. 22 cm— 1 , 1440. 26 cm” 1 , 1378. 47cm” 1 , 1339. 47cm- 1 , 1316. 48cm" 1 , 1235. 39cm" 1 , 1 196. 46cm" 1 ,
- crystal B of the compound of the formula I provided by the present invention can also be directly used for the preparation of a medicament for treating a fungal infection.
- a pharmaceutical composition comprising crystal B of a compound of formula I, and a pharmaceutically acceptable carrier can be provided.
- the term "pharmaceutically acceptable carrier” refers to a carrier for the administration of a therapeutic agent, including various excipients and diluents.
- the term refers to pharmaceutical carriers which are not themselves essential active ingredients and which are not excessively toxic after administration. Suitable carriers are well known to those of ordinary skill in the art. A full discussion of pharmaceutically acceptable excipients can be found in Remington's Pharmaceutical Scences (Mack Pub. Co., N. J. 1991).
- the pharmaceutically acceptable carrier in the composition may include liquids such as water, saline, glycerol and ethanol.
- auxiliary substances such as disintegrants, wetting agents, emulsifiers, pH buffering substances and the like may also be present in these carriers.
- the present invention obtains a novel crystalline form of a compound of formula I.
- a process for the preparation of a novel crystalline form of a compound of formula I provided by the present invention which avoids the introduction of impurities and which facilitates downstream synthesis to increase the purity of the hydrazine compound.
- the unit of weight percent by volume in the present invention is well known to those skilled in the art and, for example, refers to the weight of the solute in a 100 ml solution.
- Example 1
- the compound I solid powder 146 g was prepared by the method of U.S. Patent No. 5,202,309, and the content of HPLC was determined to be 96.1%. The liquid phase purity is shown in Fig. 6.
- Example 2
- Example 4 At 45 ° C, 3. 5 g of the compound I obtained in Example 1 was dissolved in 38 ml of ethanol, 2 ml of water was added, and stirred for 1-2 hours to completely dissolve the compound I. The solution was cooled to -50 °C, and crystal B of Compound I was precipitated. Then, 60 ml of isopropyl acetate was slowly added dropwise, and the mixture was stirred at -50 °C for 2 hours. 8% ⁇ The liquid crystal purity of the compound B 3. 35g, liquid phase purity 99. 8%. See Figure 1-3 for its XRPD, DSC, IR, and Figure 4 for liquid purity.
- Example 4 Example 4
- Example 5 At 40 ° C, 2. 5 g of the compound I obtained in Example 1 was dissolved in 48 rad of acetone, 2 ml of water was added, and stirred for 1-2 hours to completely dissolve the compound I. The solution was cooled to 20 ° C, and crystal B of Compound I was precipitated. Then, 100 ml of ethyl acetate was slowly added dropwise, and the mixture was stirred at 20 ° C for 2 hours. The liquid crystal purity was 99.8%, which was obtained by filtration. See Figure 1-3 for XRPD, DSC, IR, and Figure 4 for liquid purity.
- Example 5 Example 5
- Example 6 8 g of the compound I obtained in Example 1 was dissolved in 38 ml of methanol at 40 ° C, and 2 ml of water was added thereto, and the mixture was stirred for 1-2 hours to completely dissolve the compound I. The solution was cooled to -50 °C, and crystal B of Compound I was precipitated. 8% ⁇ The liquid crystal purity of 99. 8%. Its XRPD, DSC, IR are shown in Figures 1-3, and liquid phase purity is shown in Figure 4. Example 6
- Example 8 At 40 ° C, 9.6 g of the compound I obtained in Example 1 was dissolved in 44 ml of methanol, and 6 ml of water was added thereto, and stirred for 1-2 hours to completely dissolve the compound I. The solution was cooled to 15 ° C, and crystal B of Compound I was precipitated. Then, 150 rad of isopropyl acetate was slowly added dropwise, and the mixture was stirred at 15 ° C for 2 hours. The mixture was filtered under suction and dried in vacuo to give crystals of compound s. Its XRPD, DSC, IR are shown in Figures 1-3, and liquid phase purity is shown in Figure 4. Example 8
- Example 2 2.6 g of the compound I obtained in Example 1 was placed in a 250 ml round bottom flask, and 47.5 ml of a n-propanol round bottom flask was placed, and 2.5 rpm of water was added. The round bottom flask was placed in a 60 ° C water bath and stirred to completely dissolve the compound I. Leave at room temperature (15-2CTC) for 1-2 days. A transparent rod crystal was obtained. After crystallizing the crystal, X-ray powder diffraction was carried out, and the diffraction pattern is shown in Fig. 5. It has characteristic peaks at the following 2 ⁇ reflection angles: 5.58 ⁇ 0.2°, 8.82 ⁇ 0.2. , 9.70 ⁇ 0.2°, 16.22 ⁇ 0 ⁇ 2.
- the purity and stability of the comparative examples and the samples obtained in Examples 1-4 were compared.
- the method was as follows: The samples of Comparative Example, Example 1, Example 2, Example 3 and Example 4 were respectively placed in a sealed place for 25 days, and then the content of the sample (liquid phase purity) was analyzed.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2805962A CA2805962A1 (en) | 2010-07-20 | 2011-07-20 | Crystal of peptide substance as well as the preparation method and use thereof |
US13/811,367 US8969309B2 (en) | 2010-07-20 | 2011-07-20 | Crystal of peptide substance as well as the preparation method and use thereof |
KR1020137004312A KR101596554B1 (ko) | 2010-07-20 | 2011-07-20 | 펩타이드계 물질의 결정체 및 그의 제조방법과 용도 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010230751.4 | 2010-07-20 | ||
CN201010230751.4A CN102336818B (zh) | 2010-07-20 | 2010-07-20 | 一种肽类物质的晶体及其制备方法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012010092A1 true WO2012010092A1 (zh) | 2012-01-26 |
Family
ID=45496522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2011/077382 WO2012010092A1 (zh) | 2010-07-20 | 2011-07-20 | 一种肽类物质的晶体及其制备方法和用途 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8969309B2 (zh) |
KR (1) | KR101596554B1 (zh) |
CN (1) | CN102336818B (zh) |
CA (1) | CA2805962A1 (zh) |
WO (1) | WO2012010092A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3150624A4 (en) * | 2014-05-29 | 2017-12-20 | Shanghai Techwell Biopharmaceutical Co., Ltd | Crystal of cyclic peptide compound, preparation method for same, and uses thereof |
CN112110991A (zh) * | 2014-12-24 | 2020-12-22 | 上海天伟生物制药有限公司 | 一种含氮杂环六肽前体的组合物及其制备方法和用途 |
CN106589073A (zh) * | 2017-01-20 | 2017-04-26 | 信泰制药(苏州)有限公司 | 提纯纽莫康定b0的方法 |
CN106749543A (zh) * | 2017-01-20 | 2017-05-31 | 信泰制药(苏州)有限公司 | 一种提纯纽莫康定b0的方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008048627A1 (en) * | 2006-10-16 | 2008-04-24 | Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag | Purification processes of echinocandin-type compounds |
US20090291996A1 (en) * | 2008-05-21 | 2009-11-26 | Ferenc Korodi | Caspofungin free of caspofungin Co |
CN101659693A (zh) * | 2008-08-27 | 2010-03-03 | 上海医药工业研究院 | 制备纽莫康定b0的方法 |
WO2010064219A1 (en) * | 2008-12-04 | 2010-06-10 | Ranbaxy Laboratories Limited | Process for the preparation of a novel intermediate for caspofungin |
-
2010
- 2010-07-20 CN CN201010230751.4A patent/CN102336818B/zh active Active
-
2011
- 2011-07-20 WO PCT/CN2011/077382 patent/WO2012010092A1/zh active Application Filing
- 2011-07-20 CA CA2805962A patent/CA2805962A1/en not_active Abandoned
- 2011-07-20 US US13/811,367 patent/US8969309B2/en active Active
- 2011-07-20 KR KR1020137004312A patent/KR101596554B1/ko active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008048627A1 (en) * | 2006-10-16 | 2008-04-24 | Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag | Purification processes of echinocandin-type compounds |
US20090291996A1 (en) * | 2008-05-21 | 2009-11-26 | Ferenc Korodi | Caspofungin free of caspofungin Co |
CN101659693A (zh) * | 2008-08-27 | 2010-03-03 | 上海医药工业研究院 | 制备纽莫康定b0的方法 |
WO2010064219A1 (en) * | 2008-12-04 | 2010-06-10 | Ranbaxy Laboratories Limited | Process for the preparation of a novel intermediate for caspofungin |
Non-Patent Citations (1)
Title |
---|
ROBERT E. S. ET AL.: "PNEUMOCANDINS FROM Zalerion arboricola I.", DISCOVERY AND ISOLATION. THE JOURNAL OF ANTIBIOTICS., vol. 45, no. 12, 25 December 1992 (1992-12-25), pages 1853 - 1866 * |
Also Published As
Publication number | Publication date |
---|---|
CN102336818A (zh) | 2012-02-01 |
US20130123197A1 (en) | 2013-05-16 |
KR20130060267A (ko) | 2013-06-07 |
US8969309B2 (en) | 2015-03-03 |
CN102336818B (zh) | 2014-04-02 |
KR101596554B1 (ko) | 2016-02-22 |
CA2805962A1 (en) | 2012-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090298947A1 (en) | Polymorphic and amorphous forms of lacosamide and amorphous compositions | |
WO2013143497A1 (zh) | 一种高纯度环肽化合物及其制备方法和用途 | |
JP2019526628A (ja) | セニクリビロクメシレートの固体形態及びセニクリビロクメシレートの固体形態を製造するプロセス | |
JP6250629B2 (ja) | 高純度のシクロペプチド系物質の結晶およびその製造方法と使用 | |
US11897858B2 (en) | Salt and solid state forms of escatalopram | |
WO2012010092A1 (zh) | 一种肽类物质的晶体及其制备方法和用途 | |
IL226616A (en) | Polymorph of chemically pure nor – udca, methods for its preparation and uses for the treatment of liver disease | |
WO2018015974A1 (en) | Polymorphic forms and amorphous solid dispersion of selexipag | |
CN110167947A (zh) | 乙酸[(1S)-1-[(2S,4R,5R)-5-(5-氨基-2-氧代-噻唑并[4,5-d]嘧啶-3-基)-4-羟基-四氢呋喃-2-基]丙基]酯的固体形式 | |
JP2007524569A (ja) | ナテグリニドの結晶形 | |
WO2022258060A1 (zh) | 一种lanifibranor的晶型及其制备方法 | |
US20120220655A1 (en) | Crystalline forms of fesoterodine fumarate and fesoterodine base | |
CN108570045B (zh) | 氢溴酸山莨菪碱的晶型、其制备方法、药物组合物 | |
JPH11315088A (ja) | 脂溶性白金(ii)錯体水和物 | |
US20200283381A1 (en) | Solid state forms of elafibranor | |
CN105367492B (zh) | 他喹莫德的晶型及其制备方法、其药物组合物和用途 | |
JP6392330B2 (ja) | ポリペプチドワクチンの塩及びその製造方法と該塩を含有する医薬製品 | |
WO2018001335A1 (zh) | Nbi-98854的晶型及其制备方法和用途 | |
JP7356176B2 (ja) | トレプロスチニル一水和物結晶およびその製造方法 | |
WO2023241507A1 (zh) | 一种炔基吡啶类化合物的晶型及其制备方法 | |
KR100917593B1 (ko) | 덱시부프로펜염의 제조방법 | |
CA2613911C (en) | Crystalline forms of macrolide compounds endowed with antiinflammatory activity | |
WO2017129024A1 (zh) | 一种维利帕尼晶型a及其制备方法 | |
CN104812752B (zh) | 阿齐沙坦酯的晶型及其制备方法 | |
ES2311391B1 (es) | Forma cristalina de moxifloxacino base. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11809280 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2805962 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13811367 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 20137004312 Country of ref document: KR Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11809280 Country of ref document: EP Kind code of ref document: A1 |